Postconditioning: from experimental proof to clinical concept

Nathan Mewton1*, Fabrice Ivanès1, Martin Cour1 and Michel Ovize1

The therapeutic strategies for acute myocardial infarction in the last decade have, among other therapeutic targets, focused on myocardial reperfusion injury, which accounts for a significant part of the final infarct size. Although several experiments in the last 20 years have reported that pharmacological interventions at reperfusion might reduce myocardial reperfusion injury, this could not be consistently confirmed in animal models or human studies. An alternative to chemical modifiers, postconditioning (brief repeated periods of ischemia applied at the onset of reperfusion) is the first method proven to be efficient in different animal models and to be confirmed in a recent human study. This simple method, applied in the first minute of reperfusion, reduces the final infarct size by 30-50%. This review will focus on the postconditioning technique and show how the data from different animal models and experimental settings have advanced our understanding of both the mechanisms and the definition of an accurate protocol that is easily applicable in human patients in the setting of acute myocardial infarction.

Introduction
In the last 15 years there has been a significant improvement in the outcome of acute myocardial infarction (AMI) patients. This improvement is mainly based on the introduction of efficient reperfusion strategies, such as primary percutaneous coronary intervention (PCI) and thrombolysis (McGovern et al., 1996). Yet, coronary heart disease remains the leading cause of death in Western countries, with a mortality rate of around 10% at one year for all AMI patients. This remaining high mortality rate is partly a consequence of the myocardial reperfusion injury phenomenon (Yellon and Hausenloy, 2007). This dynamic and complex phenomenon, originally described by Jennings and Kloner in the seventies on experimental models of myocardial infarction, causes additional functional and structural damage to the acutely reperfused myocardium (Jennings et al., 1960; Kloner et al., 1974). Studies of AMI in animal models suggest that lethal reperfusion injury, which starts immediately after the opening of the culprit coronary artery, accounts for up to 50% of the final size of a myocardial infarct (Yellon and Hausenloy, 2007). In human clinical studies, this phenomenon is associated with detrimental myocardial remodeling, ventricular arrhythmias and no-reflow, and predicts a negative prognosis in myocardial infarction patients (Wu et al., 1998). Thus, lethal reperfusion injury has become a major therapeutic target in the search for improvement in AMI patient recovery and numerous strategies have been tested in experimental settings to reduce reperfusion injury.

Several investigations during the last 20 years reported that pharmacological interventions at reperfusion might reduce myocardial reperfusion injury and thus, the final infarct size. Unfortunately, owing to contradictory results, inconsistent data and a failure to translate the experimental results from in vitro to in vivo models, or from animal to human models, the first attempts to reduce reperfusion injury in humans were disappointing. The perfect example of this situation was the use of calcium channel antagonists at the onset of reperfusion. At reperfusion, there is an intracellular and mitochondrial Ca2+ overload, and this excess of Ca2+ induces cardiomyocyte death by causing hypercontracture of the heart cells and mitochondrial permeability transition pore (mPTP) opening. The use of calcium channel antagonists at reperfusion reduced this intracellular Ca2+ overload and decreased myocardial infarct size significantly in experimental studies (Klein et al., 1989). However, the results of the corresponding clinical study in humans have been negative (Boden et al., 2000).

Vinten-Johansen’s group was the first to describe the concept of postconditioning, a simple and efficient method that could significantly reduce infarct size when used during reperfusion. These authors first reported that brief episodes of ischemia, performed just at the onset of reperfusion following a prolonged ischemic insult, dramatically reduced infarct size (Hausenloy and Yellon, 2008; Zhao et al., 2003). Those results have been confirmed in several experimental preparations and in different animal species. These beneficial effects have recently been translated to the clinical setting in AMI patients undergoing PCI, with a significant 36% reduction of final infarct size, regenerating interest in the reperfusion phase as a target for cardioprotection (Staat et al., 2005).

From bringing the myocardial lethal reperfusion injury phenomenon to light to assessing and understanding new therapeutic strategies to limit lethal reperfusion injury in AMI patients, animal models have always been essential. In this Commentary, we will review the different fundamental aspects where animal models have helped in demonstrating, exploring and building the basis for clinical experimentation in the area of myocardial postconditioning.

Proof of postconditioning concept
After demonstrating that preconditioning using brief, repetitive periods of ischemia protected the myocardium from a subsequent
longer ischemic insult on experimental models (Murry et al., 1986), the idea of mechanical postconditioning emerged as a potential therapeutic strategy applicable to AMI patients. The initial, experimental proof-of-concept study was developed by Zhao et al. on an ischemia-reperfusion model of open-chest dogs (Zhao et al., 2003). In this first experiment, after 60 minutes of left anterior descending coronary artery (LAD) occlusion, reperfusion was initiated for 30 seconds followed by 30 seconds of reocclusion, which was repeated for three cycles (i.e. the total intervention lasted for 3 minutes). Reperfusion was continued for a total of 3 hours in all experiments. The results of this study showed that the infarct size in the postconditioning group was 44% smaller than that in the control group and that there was no statistical difference in infarct size between the preconditioning and postconditioning groups (Fig. 1).

In this same experimental study, the authors found that postconditioning was associated with a significant reduction of myocardial edema at the myocardial area at risk. Postconditioning reduced the accumulation of polymorphonuclear neutrophils (PMNs) in the same area and attenuated PMN adherence to the endothelium by reducing P-selectin expression on coronary vascular endothelium. Postconditioning also significantly reduced the lipid peroxidation in the myocardial area at risk compared with the control group. All those results showed that postconditioning significantly reduced the reperfusion injury phenomenon.

This observation has since been confirmed in several experimental preparations and with different animal species (rats, rabbits and mice), showing that, when applied at the time of reperfusion, postconditioning significantly reduced infarct size with results comparable to preconditioning (Bopassa et al., 2006; Bopassa et al., 2005; Kin et al., 2005; Kin et al., 2004; Tsang et al., 2004).

At first glance, the underlying mechanisms of cardioprotection seem to be complex and varied. The mechanisms involve activation of the prosurvival kinases phosphoinositide 3-kinase (PI3K)-Akt and endothelial nitric oxide synthase (eNOS) of the reperfusion injury salvage kinase (RISK) pathway (Tsang et al., 2004), interaction with the mPTP (Hausenloy et al., 2002; Bopassa et al., 2005), and activation of the endogenous receptors of adenosine (Kin et al., 2005). These underlying cellular mechanisms of postconditioning were identified using animal models of ischemia-reperfusion that are now leading progress towards direct clinical applications.

Pathophysiology of lethal reperfusion injury
Lethal reperfusion injury of the myocardium is a complex phenomenon with several etiologies. Most of the detrimental effects of reperfusion are triggered within the first minutes following the re-opening of the occluded coronary artery (Piper et al., 2004). However, most of the cellular disturbances that occur at the time of reperfusion are determined or triggered by the abnormalities induced during the ischemic period. During ischemia, the increase in anaerobic glycolysis results in the progressive accumulation of protons and lactic acid, eventually inhibiting glycolytic flux and synthesis of ATP. As the cardiomyocyte attempts to correct acidosis through the Na⁺/H⁺ exchanger, it consequently becomes loaded with Na⁺, which cannot be extruded from the cytosol since the Na⁺/K⁺ ATPase progressively fails without sufficient ATP. Secondary activation of the Na⁺/Ca²⁺ exchanger, in its reverse mode, helps pump Na⁺ out of the cell, but favors cytosolic accumulation of Ca²⁺. Prolonged ischemia induces a progressive failure of ionic homeostasis, which ultimately causes accumulation of intracellular Na⁺ and Ca²⁺, and a decline in ATP levels.

In the first minutes of reperfusion, rapid correction of acidosis through the Na⁺/H⁺ exchanger, the Na⁺/HCO₃⁻ symporter, and the washout of lactate causes secondary activation of the Na⁺/Ca²⁺ exchanger in the reverse mode and aggravates cytosolic Ca²⁺ accumulation. Abrupt re-exposure of the ischemia-inhibited mitochondrial respiratory chain to oxygen generates a membrane potential to drive ATP synthesis, which leads to a rapid overload of Ca²⁺ in the matrix and massive production of oxygen-derived free radicals.
free radicals. These two factors trigger the mPTP to open (Crompton, 1999).

Under normal physiological conditions, the mitochondrial inner membrane is impermeable to almost all metabolites and ions, and the mPTP is in a closed conformation. Under some stress conditions, the mPTP may open and allow the equilibration of molecules that are smaller than approximately 1500 daltons. Osmotic force generated by matrix proteins results in matrix swelling, leading to further rupture of the outer membrane and the release of proapoptotic factors, such as cytochrome c, into the cytosol. In addition, disruption of the mitochondrial membrane potential also causes the ATP synthase to behave as an ATPase and accelerate energy depletion secondary to the ischemic insult (Halestrap et al., 2004; Kroemer et al., 1998). In the isolated rat heart model, Di Lisa et al. demonstrated that the cytosolic release of NAD+, presented as a surrogate marker of mPTP opening, occurs at the time of reperfusion following a prolonged ischemic insult (Di Lisa et al., 2001). Griffiths and Halestrap used the [3H]2-deoxyglucose ([3H]2-DG) entrapment technique to investigate the kinetics of in situ mPTP opening, and demonstrated that mPTP opening does not happen during ischemia, but occurs within the first 5 minutes of reflow following a 30-minute period of ischemia in the isolated rat heart (Griffiths and Halestrap, 1995). Importantly, the time course of mPTP opening appeared to match the rapid correction of pH that occurs at reperfusion. Recent in vivo studies support this concept by showing that postconditioning may mediate its cardioprotective effects through prolonged transient acidosis during the early reperfusion phase (Cohen et al., 2008).

Exploring the mechanisms of postconditioning
Numerous experimental studies demonstrate a central role for mitochondria and its mPTP in the process of lethal myocardial reperfusion injury. All these studies have assessed the interaction between the mPTP opening, together with the cascade of cytotoxic events that it induces, and the postconditioning interventions.

In a rabbit model of ischemia-reperfusion, Argaud et al. found that both mechanical postconditioning and chemical postconditioning with cyclosporin A (CsA) or NIM811, a specific inhibitor of the mPTP that was given 1 minute before reperfusion, limit infarct size by at least 45% compared with control animals. They also showed that both mechanical and chemical postconditioning increase the Ca2+ load that is required to open the mPTP (Argaud et al., 2005a; Argaud et al., 2005b). Thus, specific inhibition of mPTP opening at reperfusion provided powerful antinecrotic and anti-apoptotic protection to the ischemic myocardium (Fig. 2).

Additional evidence for a major role of the mPTP in lethal reperfusion injury recently came from the use of transgenic mice lacking cyclophilin D (CypD) (Baines et al., 2005; Nakagawa et al., 2005). CypD, which is recognized as a key molecular component of the mPTP, is a mitochondrial member of the family of peptidyl-prolyl cis-trans isomerases (PPIases). Although still debated, it was reported that, in the presence of a high matrix Ca2+ concentration, CypD modifies the conformation of the inner membrane proteins to form a mega-channel. The molecular structure of the mPTP remains poorly known and, besides CypD, might involve various proteins including voltage-dependent anion channel (VDAC) or adenine nucleotide translocator (ANT); unfortunately, their precise role is still elusive and no pharmacological agent targeting these proteins is currently available for clinical trials (Leung and Halestrap, 2008; Rasola and Bernardi, 2007). CsA is considered to inhibit mPTP opening by preventing the binding of CypD to the inner membrane. In vivo, CypD-deficient mice develop smaller infarcts after a prolonged coronary artery occlusion followed by reperfusion (Baines et al., 2005; Nakagawa et al., 2005). Recently, Lim et al. reported that CypD-deficient mice cannot be postconditioned, further suggesting that lethal reperfusion injury is mediated by mPTP opening (Lim et al., 2007). These results strongly support the proposal that mPTP opening, triggered by mitochondrial Ca2+ overload and overproduction of reactive oxygen species, plays a central role in lethal reperfusion injury.

Inhibition of mPTP opening.
(A) A typical example of Ca2+-induced mPTP opening recordings in mitochondria that were isolated from control (Ctrl), preconditioned (PreC) and postconditioned (PostC) animals. mPTP opening was defined as a massive release of Ca2+ by mitochondria after a progressive Ca2+ overload of the suspension medium. The Ca2+ required for mPTP opening was significantly increased compared with animals in the control group. Postconditioning, preconditioning and NIM811 (a nonimmunosuppressive derivative of cyclosporin A that specifically inhibits opening of the mPTP) inhibited mPTP opening equally. (B) Inhibition of the mPTP resulted in a significant reduction of infarct size. The area of necrosis was reduced by a comparable extent in the preconditioned, postconditioned and NIM811 groups. *P<0.05 vs control.
Hausenloy et al. first reported that CsA, given at the time of reperfusion, could limit infarct size in the isolated rat heart (Hausenloy et al., 2002). Furthermore, Argaud et al. reported that the mPTP of mitochondria that were isolated from the risk region of postconditioned hearts displayed an enhanced resistance to Ca2+ overload (Argaud et al., 2005a). This pattern of inhibition of mPTP opening by postconditioning was very similar to that observed in hearts treated with the mPTP inhibitor NIM811 at the onset of reperfusion, as well as to that of preconditioned rabbits.

Developing practical aspects of postconditioning

Work in animal models set the therapeutic time frame for postconditioning. The mPTP opening triggered by the Ca2+ overload occurs in the first minute following reperfusion, and postconditioning strategies need to be applied at this crucial time. During the whole ischemic period, the mPTP remains closed and preconditioning does not influence its opening (Argaud et al., 2005a). This pattern of inhibition of mPTP opening by postconditioning was very similar to that observed in hearts treated with the mPTP inhibitor NIM811 at the onset of reperfusion, as well as to that of preconditioned rabbits.

Ischemic postconditioning is an unmet opportunity to determine whether lethal reperfusion injury might exist in the human heart, and whether it might represent a new therapeutic target to further decrease infarct size and improve clinical outcome. Between 2004 and 2007, we performed three small Phase II clinical trials aimed at demonstrating: (1) whether ischemic postconditioning could reduce infarct size and improve myocardial functional recovery several months after PCI, and (2) whether pharmacological inhibition of mPTP opening by the commercially available mPTP inhibitor CsA could represent a pharmacological alternative to ischemic postconditioning in AMI patients. We found that PCI postconditioning reduced infarct size by 30-40%, and that this protection persisted for 6 months post-AMI, with a significant

Fig. 3. Reduction of cardiac enzyme release by CsA in humans. (A) Serum creatine kinase (CK) was measured every 4 hours on day 1, and every 6 hours on days 2 and 3, after coronary reperfusion. Curves for the control and CsA groups are shown in A. CsA administration (Adm.) resulted in a significant reduction in infarct size of approximately 40%, as measured by creatine kinase release. (B) Serum troponin I (TnI) was measured every 4 hours on day 1, and every 6 hours on days 2 and 3, after coronary reperfusion. Curves for the control and CsA groups are shown in B. CsA administration did not result in a significant reduction in infarct size as measured by troponin I release (the bars denote the SE). (C) The area under the curve (AUC) for serum creatine kinase release was expressed as a function of the circumferential extent of abnormally contracting segments (ACS), an estimate of the area at risk. There was a significant correlation between the two variables in the control group (r²=0.60). Data points for the CsA group (r²=0.34) lie below the regression line for the control group. These data indicate that, for any given area at risk, CsA administration was associated with a reduction in the resulting infarct size, as measured by creatine kinase release. This difference was significant by analysis of covariance (P=0.006). (D) There was also a significant correlation between the AUC for troponin I release and the area at risk in the control group (r²=0.54). Data points for the CsA group (r²=0.26) lie below the regression line for the control group. These data indicate that, for any given area at risk, CsA administration was associated with a reduction in the resulting infarct size, as measured by troponin I release. This difference was confirmed to be significant by analysis of covariance (P=0.002).
improvement in contractile function continuing for 1 year after infarction (Staat et al., 2005; Thibault et al., 2008). More recently, we reported that CsA attenuates infarct size, as indicated by cardiac enzyme release during the first 3 days of reperfusion and by magnetic resonance imaging (MRI) at day 5 after reflow (Fig. 3) (Piot et al., 2008).

All of the positive results in the small Phase II trials have applied, and confirmed, the findings of the numerous experimental animal studies. However, the widespread use of these cardioprotective therapies in humans requires a demonstration showing that their application to a large number of patients improves clinical outcomes.

Potential limitations of postconditioning in the clinical setting

The principal limitation of the mechanical postconditioning technique is that it can only be applied in the setting of primary PCI. In patients where reperfusion is applied and obtained by pharmacological thrombolysis, mechanical postconditioning cannot be performed.

Another limitation to the mechanical postconditioning procedure is the recent emergence of the thromboaspiration technique in the primary PCI strategy. This technique consists of aspirating the culprit coronary thrombus with a specific dedicated catheter just before coronary reopening with balloon dilatation and stenting. Thromboaspiration has recently been shown to improve both the final myocardial blood flow and the 1-year clinical outcome in patients with AMI compared with conventional treatment (Svilas et al., 2008; Vlaar et al., 2008). There is no published evidence that this technique might interfere with the mechanical postconditioning, yet the thromboaspiration procedure usually re-establishes a significant blood flow in the culprit coronary artery, and the delay between applying thromboaspiration and initiating the postconditioning ischemia-reperfusion cycle might exceed the very short time frame in which postconditioning has been shown to be efficient. Further experimental and clinical studies need to explore this question. However, pharmacological postconditioning does not suffer from those limitations, and could be applied with either thrombolysis or thromboaspiration without any evident interference. This still needs to be assessed in further clinical studies.

Conclusion

Animal models of ischemia-reperfusion have allowed us to explore the mechanisms of postconditioning and to develop a practical, applicable and, above all, successful reperfusion strategy to our patients. Postconditioning might be the next therapy to improve cardiovascular outcome in AMI after primary PCI, although this has to be confirmed in larger clinical trials. In the future, these models will be essential to improve the practical aspects of the different postconditioning techniques, to explore new potential therapeutic targets, and to broaden our therapies to new groups of ischemic patients.

ACKNOWLEDGEMENTS

N.M. was supported by a research grant from the French Federation of Cardiology

COMPETING INTERESTS

The authors declare no competing financial interests.

REFERENCES


